PBS pricing keeps prescribers in the dark
More transparency is needed about the pricing of Pharmaceutical Benefits Scheme’s (PBS) medicines, according to a new study reported in the May edition of Australian Health Review, the peer-reviewed journal of the Australian Healthcare and Hospitals Association.
“Timely access to the medicines that Australians need at a cost individuals and the community can afford is one of the key objectives of Australia’s National Medicines Policy (NMP) and the PBS plays an important role in meeting this objective,” Dr Jane Robertson, University of Newcastle, said.
Changes to the price of PBS medicines to consumers has a significant impact on demand and may undermine the objectives of Australia’s National Medicines Policy, the new study reveals.
